Impact of Autoantibody to Serpin B13 as a Biomarker in Humans With Type 1 Diabetes
Our early studies in children with recent onset Type 1 Diabetes (T1D) revealed that patients with autoantibody (AA) to serpin B13 maintain higher c-peptide levels during the first year postdiagnosis compared with those that are negative for this AA (Figure 3). To further validate serpin B13 AA as a biomarker of slower progression of islet pathology we have recently started examining subjects that are healthy but at risk for developing T1D. Our translational research has been contingent upon gaining access to biosamples from several sources including the Belgian Diabetes Registry, Type 1 Diabetes TrialNet and Diabetes Prevention Trial-1.
« back to all projects